J&J and AbbVie present early trispecific antibody data for multiple myeloma at ASH meeting

At the American Society of Hematology (ASH) meeting, Johnson & Johnson and AbbVie are slated to share early clinical data on trispecific antibodies targeting multiple myeloma. These next‑generation molecules are designed to bind three distinct targets, aiming to overcome tumor resistance mechanisms that limit the durability of current therapies.

The concept builds on a decade of bispecific antibody development that began with Amgen's Blincyto approval in 2014. Since then, several companies have expanded bispecific formats to treat blood cancers and even lung cancer. Trispecifics represent the next step, potentially offering broader immune engagement.

Presentations will focus on pre‑clinical and early‑phase trial results, highlighting how the three‑pronged approach may produce longer‑lasting anti‑tumor effects. While the data are still early, the companies hope the findings will signal a meaningful advance for patients with multiple myeloma.